Table of Contents
Lung Cancer International
Volume 2014 (2014), Article ID 810786, 6 pages
http://dx.doi.org/10.1155/2014/810786
Research Article

Analysis of Expression of Vascular Endothelial Growth Factor A and Hypoxia Inducible Factor-1alpha in Patients Operated on Stage I Non-Small-Cell Lung Cancer

1Thoracic Surgery, University General Hospital of Albacete, 37 Hermanos Falcó Street, 02006 Albacete, Spain
2Thoracic Surgery, University General Hospital of Valencia and Surgery Department of the School of Medicine and Odontology, University of Valencia, 15 Blasco Ibáñez Avenue, 46010 Valencia, Spain
3Thoracic Surgery, University General Hospital of Valencia, Tres Creus Avenue, 46014 Valencia, Spain

Received 10 October 2013; Revised 15 December 2013; Accepted 26 December 2013; Published 10 February 2014

Academic Editor: Akira Iyoda

Copyright © 2014 Antonio Francisco Honguero Martínez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. R. Youlden, S. M. Cramb, and P. D. Baade, “The international epidemiology of lung cancer: geographical distribution and secular trends,” Journal of Thoracic Oncology, vol. 3, no. 8, pp. 819–831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. E. . Fernández, J. M. Borrás, F. Levi, A. Schiaffino, M. García, and C. Vecchia, “Mortalidad por cáncer en España,” Medicina Clinica, vol. 114, pp. 449–451, 2000. View at Google Scholar
  3. F. C. Detterbeck, D. J. Boffa, and L. T. Tanoue, “The new lung cancer staging system,” Chest, vol. 136, no. 1, pp. 260–271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Encuentra, F. L. Ríos, E. Conde et al., “Composite anatomical-clinical-molecular prognostic model in non-small cell lung cancer,” The European Respiratory Journal, vol. 37, pp. 136–142, 2011. View at Google Scholar
  5. J. K. Field, T. Liloglou, A. Niaz et al., “EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration,” The European Respiratory Journal, vol. 34, no. 6, pp. 1477–1486, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Junker, “Prognostic factors in stage I/II non-small cell lung cancer,” Lung Cancer, vol. 33, supplement 1, pp. S17–S24, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Google Scholar · View at Scopus
  8. G. H. Algire, H. W. Chalkey, F. Y. Legallis, and H. D. Park, “Vascular reactions of normal and malignant tissues in vivo. Vascular reactions in mice to wounds and to normal and neoplastic transplants,” Journal of the National Cancer Institute, vol. 6, pp. 73–85, 1945. View at Google Scholar
  9. R. M. Bremnes, C. Camps, and R. Sirera, “Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood,” Lung Cancer, vol. 51, no. 2, pp. 143–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. J. O'Byrne, M. I. Koukourakis, A. Giatromanolaki et al., “Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer,” British Journal of Cancer, vol. 82, no. 8, pp. 1427–1432, 2000. View at Google Scholar · View at Scopus
  11. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Google Scholar · View at Scopus
  12. A. P. Levy, N. S. Levy, and M. A. Goldberg, “Post-transcriptional regulation of vascular endothelial growth factor by hypoxia,” The Journal of Biological Chemistry, vol. 271, no. 5, pp. 2746–2753, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. W. D. Travis, E. Brambilla, H. K. Müller-Hermelink, and C. C. Harris, Eds., Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, World Health Organization Classifications of Tumours, IARC Press, Lyon, France, 2004.
  14. L. Crinò, W. Weder, J. van Meerbeeck, E. Felip, and ESMO Guidelines Working Group, “Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, supplement 5, pp. S103–S115, 2010. View at Google Scholar
  15. W. R. Smythe, “Treatment of stage I non-small cell lung carcinoma,” Chest, vol. 123, no. 1, 2003. View at Google Scholar · View at Scopus
  16. M. J. Kim, H.-G. Kang, S. Y. Lee et al., “AKT1 polymorphisms and survival of early stage non-small cell lung cancer,” Journal of Surgical Oncology, vol. 105, no. 2, pp. 167–174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. P. A. Lario, B. C. García, and E. M. Elizondo, “Expresión de proteínas relacionadas con resistencia en el cáncer de pulmón,” Cirugía Española, vol. 79, pp. 46–56, 2006. View at Google Scholar
  18. M. Liao, H. Wang, Z. Lin, J. Feng, and D. Zhu, “Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer,” Lung Cancer, vol. 33, no. 2-3, pp. 125–132, 2001. View at Google Scholar
  19. K.-I. Minami, Y. Saito, H. Imamura, and A. Okamura, “Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung,” Lung Cancer, vol. 38, no. 1, pp. 51–57, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Maestro de las Casas, R. R. Sánchez, M. T. Sanz Casla, A. T. García, and J. L. Balibrea, “Cáncer de pulmón: hacia un nuevo concepto de marcador tumoral,” Cirugía Española, vol. 63, pp. 53–60, 1998. View at Google Scholar
  21. J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Google Scholar · View at Scopus
  22. P. Jaakkola, D. R. Mole, Y.-M. Tian et al., “Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation,” Science, vol. 292, no. 5516, pp. 468–472, 2001. View at Google Scholar · View at Scopus
  23. S. Enatsu, A. Iwasaki, T. Shirakusa et al., “Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung,” European Journal of Cardio-Thoracic Surgery, vol. 29, no. 6, pp. 891–895, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Giatromanolaki, M. I. Koukourakis, E. Sivridis et al., “Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival,” British Journal of Cancer, vol. 85, no. 6, pp. 881–890, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. S. J. Kim, Z. N. Rabbani, M. W. Dewhirst et al., “Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer,” Lung Cancer, vol. 49, no. 3, pp. 325–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Höckel and P. Vaupel, “Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects,” Journal of the National Cancer Institute, vol. 93, no. 4, pp. 266–276, 2001. View at Google Scholar · View at Scopus
  27. P. Zhan, J. Wang, X.-J. Lv et al., “Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis,” Journal of Thoracic Oncology, vol. 4, no. 9, pp. 1094–1103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Delmotte, B. Martin, M. Paesmans et al., “The role of vascular endothelial growth factor in the survival of patients with lung cancer: a systematic literature review and meta-analysis,” Revue des Maladies Respiratoires, vol. 19, no. 5, pp. 577–584, 2002. View at Google Scholar · View at Scopus
  29. J.-J. Hung, M.-H. Yang, H.-S. Hsu, W.-H. Hsu, J.-S. Liu, and K.-J. Wu, “Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer,” Thorax, vol. 64, no. 12, pp. 1082–1089, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Lidgren, Y. Hedberg, K. Grankvist, T. Rasmuson, J. Vasko, and B. Ljungberg, “The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma,” Clinical Cancer Research, vol. 11, no. 3, pp. 1129–1135, 2005. View at Google Scholar · View at Scopus
  31. M. Volm and R. Koomägi, “Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer,” Anticancer Research, vol. 20, no. 3, pp. 1527–1533, 2000. View at Google Scholar · View at Scopus
  32. G. Powis and L. Kirkpatrick, “Hypoxia inducible factor-1α as a cancer drug target,” Molecular Cancer Therapeutics, vol. 3, no. 5, pp. 647–654, 2004. View at Google Scholar · View at Scopus
  33. W.-H. Kuo, C.-M. Shih, C.-W. Lin et al., “Association of hypoxia inducible factor-1α polymorphisms with susceptibility to non-small-cell lung cancer,” Translational Research, vol. 159, no. 1, pp. 42–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. V. R. Adams and R. D. Harvey, “Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology,” American Journal of Health-System Pharmacy, vol. 67, supplement 1, pp. S3–S9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Reck, J. Von Pawel, P. Zatloukal et al., “Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1227–1234, 2009. View at Publisher · View at Google Scholar · View at Scopus